| Project/Area Number |
18K16284
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 55010:General surgery and pediatric surgery-related
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
Hato Yukari 名古屋市立大学, 医薬学総合研究院(医学), 研究員 (20721864)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 乳癌 / RNF5 / オートファジー |
|---|
| Outline of Final Research Achievements |
Resistance to endocrine therapies remains a major challenge in the treatment for ERα-positive breast cancer patients. Recently, RNF5, a proteolytic ubiquitin ligase, has been reported to be involved in the growth of breast cancer. In our preliminary experiments, we found positive association between decreased mRNA expression of the RNF5 gene in breast cancer tissues and poor prognosis. In order to validate the results of our preliminary experiments, we investigated the relationship between RNF5 mRNA expression and clinicopathological factors and prognosis using 625 breast cancer patients with long-term follow-up. RNF5 mRNA expression was positively correlated with high grade, and estrogen receptor-negative. However, no significant difference was observed in the association between RNF5 mRNA expression and prognosis, although there was a trend toward poor prognosis in both disease-free survival and overall survival in patients with reduced RNF5 mRNA expression.
|
| Academic Significance and Societal Importance of the Research Achievements |
乳癌の増殖にユビキチンリガーゼのひとつRNF5が関与していることが報告された。この報告を検証するために、当施設で長期フォローアップを行った約600例の乳癌症例を用いて、RNF5遺伝子の mRNA発現と臨床病理学的因子および予後との検討を行った。しかし、残念ながらRNF5 mRNA発現と予後との間に明確な関連性は認められず、RNF5が乳癌治療の標的となる可能性は低いと考えられた。
|
